NCT05470413Phase 3Status unknown
Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata
A Randomized, Double-Blinded, and Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata
In the register
The register attaches this trial to Ivarmacitinib (ARQ-252), currently at “Filed with regulator” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Status unknown
- Declared phase
- Phase 3
- Sponsor
- Reistone Biopharma Company Limited
- Participants (registry)
- 330
- Start
- April 2022
- Primary completion
- October 2023
- Study completion
- February 2024
- Last registry update
- September 2023
- Countries
- China
Conditions studied: Alopecia Areata
Interventions: SHR0302, SHR0302, Placebo
Other trials of Ivarmacitinib (ARQ-252)
A Phase II Study in Patients With Alopecia Areata
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.